Effect of fecal microbiota transplantation in patients with slow transit constipation and the relative mechanisms based on the protein digestion and absorption pathway
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Xie L, Xu C, Fan Y, Li Y, Wang Y, Zhang X, Yu S, Wang J, Chai R, Zhao Z, Jin Y, Xu Z, Zhao S, Bian Y
Journal
Journal of translational medicine
Year
2021
Keywords:
Fecal microbiota transplantation (FMT), Slow transit constipation (STC), The protein digestion and absorption pathway
BACKGROUND: Fecal microbiota transplantation (FMT) is considered an effective treatment for slow transit constipation (STC); nevertheless, the mechanism remains unclear. METHODS: In this study, eight patients with STC were selected according to the inclusion and exclusion criteria; they then received three treatments of FMT. The feces and serum of STC patients were collected after each treatment and analyzed by integrating 16 s rRNA microbiome and metabolomic analyses. RESULTS: The results showed that the percentage of clinical improvement reached 62.5% and the rates of patients' clinical remission achieved 75% after the third treatment. At the same time, FMT improved the Wexner constipation scale (WCS), the Gastrointestinal Quality-of-Life Index (GIQLI) and Hamilton Depression Scale (HAMD). Fecal microbiome alpha diversity and beta diversity altered significantly after FMT. Analysis of the 16 s rRNA microbiome showed that the numbers of Bacteroidetes (Prevotell/Bacteroides) and Firmicute (Roseburia/Blautia) decreased, whereas Actinobacteria (Bifidobacterium), Proteobacteria (Escherichia), and Firmicute (Lactobacillus) increased after FMT. The metabolomics analyses showed that the stool of FMT-treated patients were characterized by relatively high levels of N-Acetyl-L-glutamate, gamma-L-glutamyl-L-glutamic acid, Glycerophosphocholine, et al., after FMT. Compared with baseline, the serum of treated patients was characterized by relatively high levels of L-Arginine, L-Threonine, Ser-Arg, Indoleacrylic acid, Phe-Tyr, 5-L-Glutamyl-L-alanine, and lower levels of Erucamide after the treatment. The correlation analysis between the metabolites and gut microbiota showed a significant correlation. For example, L-Arginine was positively correlated with lactobacillus, et al. L-Threonine was positively correlated with Anaerovibrio, Sediminibacterium but negatively correlated with Phascolarctobacterium. Erucamide had significant negative correlations with Sediminibacterium and Sharpea, while being positively correlated with Phascolarctobacterium. Enriched KEGG pathways analysis demonstrated that the protein digestion and absorption pathways gradually upregulated with the increase of FMT frequency. The L-Arginine and L-Threonine were also involved in the pathway. A large amount of Na + was absorbed in the pathway, so that it might increase mucus secretion and electrical excitability of GI smooth muscle. CONCLUSIONS: Therefore, we speculated that FMT changed the patients' gut microbiota and metabolites involved in the protein digestion and absorption pathways, thereby improving the symptoms of STC. Study on the effectiveness and safety of FMT in the treatment of STC. The study was reviewed and approved by Ethics Committee of Tianjin People's Hospital (ChiCTR2000033227) in 2020.
Experiment 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-3
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Response to transplant Response to transplant,response to transplant
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Fecal microbiota transplant patients at baseline (B1)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Post-fecal microbiota transplant patients (B2)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- This group consists of post-FMT patients after the first fecal microbiota transplant.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 8
- Group 1 sample size Number of subjects in the case (exposed) group
- 8
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 6 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-3
Source: Figure 4A
Description: LEfSe analysis with an LDA value of > 2 displayed the dominant microbiomes in each group (B1 & B2).
Abundance in Group 1: increased abundance in Post-fecal microbiota transplant patients (B2)
| NCBI | Quality Control | Links |
|---|---|---|
| Lactobacillaceae | ||
| Lactobacillus | ||
| Sharpea |
Signature 2
Reviewed Marked as Reviewed by KateRasheed on 2025-6-3
Source: Figure 4A
Description: LEfSe analysis with an LDA value of > 2 displayed the dominant microbiomes in each group (B1 & B2)
Abundance in Group 1: decreased abundance in Post-fecal microbiota transplant patients (B2)
| NCBI | Quality Control | Links |
|---|---|---|
| Ruminococcus |
Experiment 2
Reviewed Marked as Reviewed by KateRasheed on 2025-6-3
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Post-fecal microbiota transplant patients (B3)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- This group consists of post-FMT patients after the second fecal microbiota transplant.
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-3
Source: Figure 4B
Description: LEfSe analysis with an LDA value of > 2 displayed the dominant microbiomes in each group (B1 & B3).
Abundance in Group 1: increased abundance in Post-fecal microbiota transplant patients (B3)
Revision editor(s): Victoria
Signature 2
Reviewed Marked as Reviewed by KateRasheed on 2025-6-3
Source: Figure 4B
Description: LEfSe analysis with an LDA value of > 2 displayed the dominant microbiomes in each group (B1 & B3).
Abundance in Group 1: decreased abundance in Post-fecal microbiota transplant patients (B3)
| NCBI | Quality Control | Links |
|---|---|---|
| Mycoplana | ||
| Prevotellaceae | ||
| Anaerostipes | ||
| Lachnospiraceae |
Revision editor(s): Victoria
Experiment 3
Reviewed Marked as Reviewed by KateRasheed on 2025-6-3
Differences from previous experiment shown
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Post-fecal microbiota transplant patients (B4)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- This group consists of post-FMT patients after the third fecal microbiota transplant.
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-3
Source: Figure 4C
Description: LEfSe analysis with an LDA value of > 2 displayed the dominant microbiomes in each group (B1 & B4).
Abundance in Group 1: increased abundance in Post-fecal microbiota transplant patients (B4)
Revision editor(s): Victoria
Signature 2
Reviewed Marked as Reviewed by KateRasheed on 2025-6-3
Source: Figure 4C
Description: LEfSe analysis with an LDA value of > 2 displayed the dominant microbiomes in each group (B1 & B4).
Abundance in Group 1: decreased abundance in Post-fecal microbiota transplant patients (B4)
| NCBI | Quality Control | Links |
|---|---|---|
| Ralstonia | ||
| Acidimicrobiales | ||
| Acidimicrobiia | ||
| Caulobacteraceae | ||
| Caulobacterales | ||
| Candidatus Xiphinematobacter | ||
| Mycoplana | ||
| Sphingomonas | ||
| Phascolarctobacterium | ||
| Gemm 3Gemm 3 |
Revision editor(s): Victoria
Retrieved from "https://bugsigdb.org/w/index.php?title=34852831&oldid=204943"
